Corrigendum to “Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission” [Journal of Controlled Release 294 (2019)216–225](S0168365918307302)(10.1016/j.jconrel.2018.12.027)

Subhra Mandal, Guobin Kang, Pavan Kumar Prathipati, You Zhou, Wenjin Fan, Qingsheng Li, Christopher J. Destache

Research output: Contribution to journalComment/debate

Abstract

The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Number of pages1
JournalJournal of Controlled Release
Volume304
DOIs
StatePublished - Jun 28 2019
Externally publishedYes

Fingerprint

Drug Combinations
HIV-1
Pharmacokinetics
Drug Interactions
Pharmaceutical Preparations
Nanoparticles
Animal Care Committees
Anti-Retroviral Agents
Reverse Transcriptase Inhibitors
Tissue Distribution
Nucleosides
Ethics
Emotions
Acquired Immunodeficiency Syndrome
Pre-Exposure Prophylaxis
Emtricitabine
corrigendum
GS-7340
Health
JTK 303

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{1bbe122eefe24cf78f43adda5f3fa1c2,
title = "Corrigendum to “Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission” [Journal of Controlled Release 294 (2019)216–225](S0168365918307302)(10.1016/j.jconrel.2018.12.027)",
abstract = "The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.",
author = "Subhra Mandal and Guobin Kang and Prathipati, {Pavan Kumar} and You Zhou and Wenjin Fan and Qingsheng Li and Destache, {Christopher J.}",
year = "2019",
month = "6",
day = "28",
doi = "10.1016/j.jconrel.2019.05.002",
language = "English (US)",
volume = "304",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Corrigendum to “Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination

T2 - A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission” [Journal of Controlled Release 294 (2019)216–225](S0168365918307302)(10.1016/j.jconrel.2018.12.027)

AU - Mandal, Subhra

AU - Kang, Guobin

AU - Prathipati, Pavan Kumar

AU - Zhou, You

AU - Fan, Wenjin

AU - Li, Qingsheng

AU - Destache, Christopher J.

PY - 2019/6/28

Y1 - 2019/6/28

N2 - The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85065240978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065240978&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.05.002

DO - 10.1016/j.jconrel.2019.05.002

M3 - Comment/debate

C2 - 31082646

AN - SCOPUS:85065240978

VL - 304

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -